Secondary Strongyloides stercoralis prophylaxis in patients with human T-cell lymphotropic virus type 1 infection: report of two cases.
Secondary ivermectin prophylaxis for strongyloidiasis in two patients with human T-cell lymphotropic virus type 1 (HTLV-1)-associated malignancies and fully treated complicated strongyloidiasis is described. Treatment was well tolerated and neither patient developed further manifestations of hyperinfection. As treatment failure for complicated strongyloidiasis has been documented in severely immunosuppressed patients, secondary prophylaxis may be indicated.
Peters
Laurenna
L
Postgraduate Training Program, Division of Infectious Diseases, University of British Columbia, Vancouver, Canada.
McCarthy
Anne E
AE
Faught
Carolyn
C
D000328:Adult; D000818:Animals; D000969:Antinematodal Agents / Q000627:therapeutic use*; D018890:Chemoprevention; D017809:Fatal Outcome; D005260:Female; D015490:HTLV-I Infections / Q000150:complications*; D015368:Human T-lymphotropic virus 1 / Q000302:isolation & purification; D006801:Humans; D007559:Ivermectin / Q000627:therapeutic use*; D015458:Leukemia, T-Cell / Q000150:complications; D008228:Lymphoma, Non-Hodgkin / Q000150:complications; D008297:Male; D017171:Strongyloides stercoralis / Q000187:drug effects* / Q000302:isolation & purification; D013322:Strongyloidiasis / Q000150:complications* / Q000469:parasitology / Q000517:prevention & control
D000969:Antinematodal Agents; D007559:Ivermectin